An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer.
Ruta V, Naro C, Pieraccioli M, Leccese A, Archibugi L, Cesari E, Panzeri V, Allgöwer C, Arcidiacono PG, Falconi M, Carbone C, Tortora G, Borrelli F, Attili F, Spada C, Quero G, Alfieri S, Doglioni C, Kleger A, Capurso G, Sette C.
Ruta V, et al. Among authors: kleger a.
Cell Rep Med. 2024 Feb 20;5(2):101411. doi: 10.1016/j.xcrm.2024.101411. Epub 2024 Feb 6.
Cell Rep Med. 2024.
PMID: 38325381
Free PMC article.